Shares of MannKind rose on Monday after the drugmaker surpassed Wall Street's estimates for second quarter earnings and indicated several new drugs are in the company's development pipeline. Hakan S. Edstrom , president and CEO of the California-based drug company that has its manufacturing facility and pharmaceutical development operations in Danbury, said during a conference call with investors Monday that feasibility studies are being conducted on at least two new drug candidates including treatments for pain and pulmonary hypertension, a type of high blood pressure that affects arteries in the lungs and heart.